For health systems that have already built a coordinated program, these updates serve as a useful checkpoint. For those still working toward one, these guidelines offer a clear starting point. Establishing the right opioid stewardship program now provides a foundation to build on should this guidance become more formalized in the future.
Understanding what CMS and Joint Commission opioid stewardship standards changed
The updated guidance comes from three sources; each one approaches clinical activities related to opioid stewardship from a different angle.
- CMS HH-ORAE (CMS819v4) Tracks how often patients receive a naloxone or nalmefene rescue dose within 12 hours of an inpatient opioid administration outside the operating room. Results are publicly reported with no risk adjustment and no exclusions, giving a direct view into how frequently opioid-related adverse events are occurring at a facility.
- CMS Safe Use of Opioids (CMS506v8) looks at the discharge processes. It flags inpatient stays where a patient left the hospital on two or more opioids, or on an opioid combined with a Schedule IV benzodiazepine. Outside of a small number of disease-specific exclusions, every qualifying discharge counts. A lower score on both CMS measures reflects better performance.
- Joint Commission NPG Goal 6 focuses on prevention rather than after-the-fact measurement. It calls on hospital leaders to work with clinical staff to identify and acquire the equipment needed to monitor patients at high risk for adverse outcomes from opioid treatment, and to document that active monitoring is taking place.
More broadly, The Joint Commission has stepped back from prescriptive, line-item metrics. In their place is a broader, patient-centered approach to pain management, one that gives health systems room to decide how they meet the intent of its standards rather than follow a dictated set of steps.
The underlying priority holds across all three updates: greater visibility into opioid use, paired with the ability to act on it.
What the new opioid stewardship guidance signals for the future
A growing body of clinical evidence underscores why opioid stewardship matters. A closed-claims analysis cited in the CMS eCQM rationale found that 97% of opioid adverse events could have been avoided with better monitoring and response. Each surgical hospitalization tied to an opioid adverse event adds $8,225 in cost, and patients who take both opioids and benzodiazepines face a fatal overdose rate ten times higher than those who do not.
Together, these figures show the toll on both patient outcomes and hospital operations. As CMS and The Joint Commission raise expectations around opioid monitoring, systematic, well-documented tracking of opioid use is becoming a baseline expectation across the industry.